Curriculum Vitae

ADAM SPLAVER, MD, FACC, FACP, FASE, RPVI

*** * **** **. *** 38E

New York, NY 10017

adb17a@r.postjobfree.com

954-***-****

EMPLOYMENT

*/**** - ******* ******* ****** Podcast with Dr. Adam Splaver on the Apple Podcast App and Stitcher

7/2014 – 12/31/2019 NanoHealth Associates – Partner and Co-Founder Clinical and Preventative Cardiology/Internal Medicine 3/2015 –3/2019 Diagnostic Partners – Interpret Echocardiographic studies remotely 1994 – 2017 Consultant – MedMaster Inc. - Edit books for publication such as Cardiology Made Ridiculously Simple, USMLE Step 1 Made Ridiculously Simple, Acids Bases and Electrolytes Made Ridiculously Simple, Radiology Made Ridiculously Simple, Behavioral Science for USMLE Made Ridiculously Simple.

1/11/11 – 1/31/16 Memorial Healthcare System - Medical Director of Echocardiography 5 Hospitals – Memorial Regional, Memorial South, Memorial Pembroke, Memorial West and Memorial Miramar

Upgraded/migrated system from dictated to structured reporting Obtained initial IAC certification for the Memorial Hospital System – one of the largest at the time to receive certification. Managed over 70 sonographers and over 50 Echo readers Over 20,000 studies performed/year

7/2004 – 7/2014 Florida Institute for Cardiovascular Care, PA, dba Healthworx, Hollywood, FL Cardiologist

OTHER EMPLOYMENT

ACADEMIC APPOINTMENTS

2011 - 2019 University of Miami, Leonard M. Miller School of Medicine, Miami, FL Voluntary Assistant Professor of Medicine

2/2009 – 7/2014 South Florida Research Solutions, LLC Miramar, FL

2/2008- 12/2019 Nova Southeastern University, Davie, FL Clinical Assistant Professor, Dept. Internal Medicine, Div. of Cardiology EDUCATION

Fellowship

7/2001 -6/2004 Mount Sinai Medical Center, Miami Beach, FL Fellowship - Cardiology

Residency

7/1999 – 6/2001 Mount Sinai Medical Center, Miami Beach, FL Residency – Internal Medicine

Internship

1 Page

7/1998 - 6/1999 Mount Sinai Medical Center, Miami Beach, FL Internship – Internal Medicine

Medical School

9/1994 – 6/1998 Albert Einstein College of Medicine of Yeshiva University, Bronx, NY M.D.

College

9/1990 – 6/1994 Yeshiva College, New York, NY

B.A. Biology, Cum Laude

Other

9/1989 - 6/1990 Yeshivat Ohr Yerushalayim, Beit Meir, Israel BOARD

CERTIFICATIONS

2004-2024 Board Certified - ABIM – Cardiology

2004-2024 Board Certified NBE- Echocardiography

2003-2013 Diplomate - Certification Board of Nuclear Cardiology 2001-2021 Diplomate - American Board of Internal Medicine OTHER

CERTIFICATIONS

2011 - Present ARDMS RPVI - Registered Physician in Vascular Interpretation 2011 The Cenegenics Education & Research Foundation - Age Management Medicine

2014 A4M - Certification in Anti-aging and Regenerative Medicine TITLES

2013 – 2017 Member of the TAVR team – Memorial Healthcare System 2014 – 2017 Member of the Advanced Heart Failure and Transplant Team - Memorial Healthcare System

2013 – 2017t Member of the Cardiovascular Executive Committee – Memorial Healthcare System

2014 – 2017 Member of the Mitra-Clip Committee – Memorial Healthcare System HOSPITAL Memorial Regional Hospital

Memorial South

PRIVILEGES Memorial Hospital West

Memorial Hospital Miramar

Memorial Hospital Pembroke

Aventura Hospital

LICENSURE Florida Medical License

New York Medical License

Wisconsin Medical License

Pennsylvania Medical License

New Jersey Medical License

Virginia Medical License

Montana Medical License

2 Page

MEMBERSHIPS ACC, AHA, ACP-ASIM, AMA, ASE,

AWARDS / HONORS

1994 Professor Mayer Atlas Memorial Award for Excellence in Biology. Yeshiva College, New York, NY

1989 –1994 Samuel Belkin Memorial Scholarship.

Yeshiva College, New York, NY

1989 –1994 Dean’s List. (all semesters) – Yeshiva College, New York, NY LANGUAGES English, Hebrew, Spanish

EXTRACURRICULAR

2002 –2018 President and Board Member – Young Israel of Hollywood/Ft. Lauderdale, FL,

2002 -2011 First Vice President and Board Member – Brauser Maimonides Academy, Ft. Lauderdale, FL

2002 – 2004 Board Member – Cardiovascular Committee – Mount Sinai Medical Center/Miami Heart Institute, Miami Beach, FL

1994 – 1995 Associate Instructor of Biology – Yeshiva College, Cell Biology Laboratory

1993 – 1994 Teacher’s Assistant – Columbia University, Cell and Developmental Biology Laboratory

Summer 1994 Program Director – ACHY. Headed and developed a program to tutor English and Math to newly arrived Ethiopian and Russian immigrants to Haifa, Israel.

1991-1994 Assistant Director – Y.U.S.S.R. – Organized over 10 summer camp programs scattered throughout the former Soviet Union. Participated in running a summer camp program in Tallinn Estonia.

1991- 1995 Lifeguard –Yeshiva College

PUBLICATIONS

A. Manheimer-Lory, R. Monhian, A. Splaver, B. Gaynor, and B. Diamond. “Analysis of the VκI family: Germline genes form an SLE patient and expressed autoantibodies.” Autoimmunity, 1995, Vol 20, pp. 259-265.

A.Manheimer-Lory, M. Irigoyen, B. Gaynor, R. Monhian, A. Splaver, and B. Diamond. “Analysis of VκI and VλII light chain genes in the expressed B-cell repertoire.” Annals of the New York Academy of Sciences, Sept 29,1995, Vol 764, pp. 301-311. A. Splaver, S. Silos, B. Lowell, R. Valenzuela, and R. Kirsner,“Case Report: Pemphigus Vulgaris in a Patient Infected With HIV” AIDS Patient Care & Standards, June 2000, Vol 14(6), pp. 295-296. A. Splaver, G. Lamas, C. Hennekens,”Homocysteine and Cardiovascular Disease: Biological Mechanisms, Observational Epidemiology and the Need for Randomized Trials: Homocysteine and Cardiovascular Disease” In press, AHJ for August 2004. CLINICAL RESEARCH

1993 – 1994 Research Assistant – Columbia University Ofra Weinberger, PhD, Investigated the role of soluble, extracellular tat and rev particles an HIV and JC expression.

3 Page

1992 - 1992 Roth Institute Scholar – Albert Einstein College of Medicine Betty Diamond, M.D., Analyzed the role of somatic mutation on the development of antids-DNA antibodies in Lupus patients 2004 - 2011 EARLY ACS - EARLY Glycoprotein IIB/IIIa Inhibition in Non-ST-segemtn Elevation Acute Coronary Syndrome: A Ranomized, Placebo-Controilled Trial Evaluating the Clinical Benefits of Early Front-Loaded Eptifibatide in the Treatment of Patient with Non-ST-segment Elevation Acute Coronary Syndrome.

Sponsor: Schering-Plough Role: Sub- Investigator

2005 - 2007 IMPROVE IT - A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs. Simvastatin Monotherapy in High-Risk Subjects Presenting with Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial – IMPROVE IT

Sponsor: Merck Role: Sub Investigator

2005 - 2008 RE-LY STUDY Randomized Evaluation of Long term anticoagulant therapy

(RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial (RE-LY STUDY)

Sponsor: Boehringer Ingelheim Role: Sub-Investigator 2007 – 2007 ASCEND-HF Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure

Sponsor: Scios Role: Sub-Investigator

2007 – 2009 ROCKET AF STUDY A Prospective, Randomized, Double-Blind, Double- Dummy, Parallel-Group, Multicenter, Event-Driven, Non-Inferiority Study Comparing the Efficacy and Study Drug With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation Sponsor: Johnson-Johnson Role: Sub-Investigator

2007 – 2011 ARISTOTLE STUDY Apixaban for Reduction In STroke and Other ThromboemboLic Events in Atrial Fibrillation A Phase 3, active (Warfarin) controlled Randomized, Double-Blind Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects with Nonvalvular Atrial Fibrillation Sponsor: Bristol Myers Squibb Role: Sub-Investigator 2010 – 2014 ORBIT-AF – A Phase IV Outcome Registry for Better Informed Treatment of Atrial Fibrillation

4 Page

Sponsor: Duke Clinical Research Institute Role: Principal Investigator

2010 – 2011 ALECARDIO.- A Multicenter, randomized, double blind, placebo-controlled cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D). Sponsor: ROCHE Role: Sub-Investigator

2010 – 2011 REVEAL IN-OFFICE.- Implant Study, a prospective, non-randomized, multi- center post-market clinical Trial to gather evidence about the safety and feasibility of performing the implant procedure for the Reveal Insertable Cardiac Monitor (ICM) in an office or clinic setting. Sponsor: Medtronic Role: Principal Investigator

2011 – 2013 TERISA STUDY.- A Phase 4, Randomized, Double-Blind, Placebo- Controlled, Parallel Study of Ranolazine in Subjects with Chronic Stable Angina and Coronary Artery Disease with a History of Type 2 Diabetes Mellitus

Sponsor: Gilead Role: Principal Investigator

2011 – 2012 BREVIBLOC.- A Phase IV, Multicenter, Observational Study Evaluating Hemodynamic Outcomes with Brevibloc Premixed Injection (Esmolol Hydrochloride) in Patients with Supraventricular Tachycardia/Atrial Fibrillation in Medical and Neurological Intensive Care Units in the United States

Sponsor: Baxter Inc. Role: Principal Investigator

2011 - 2014 LV-BTD- Retrospective Study of Outcomes in Heart Failure Patients treated with LifeVest as Bridge to Decision

Sponsor: Zoll Role: Principal Investigator

2013 - 2014 GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In

Patients with Atrial Fibrillation (Phase II/III)

Sponsor: Boehringer Ingelheim Role: Principal Investigator 2013 – 2014 ORBIT-AF II – A Phase IV Outcomes Registry for Better Informed Treatment of Atrial Fibrillation

Sponsor: Duke Clinical Research Institute Role: Principal Investigator

5 Page

2013 – 2014 X-Vert 15693 - A prospective, randomized, open-label, parallel-group, active-controlled, multicenter study exploring the efficacy and safety of once-daily

oral rivaroxaban (BAY 59-7939) compared with that of dose- adjusted oral

vitamin K antagonists (VKA) for the prevention of cardiovascular events in subjects

with nonvalvular atrial fibrillation scheduled for cardioversion Sponsor: Bayer Healthcare Role: Principal Investigator 2013 – 2014 EFFECT AF – Relative Effectiveness of Dronedarone vs. Other Treatments of Atrial Fibrillation

Sponsor: LaSer Research Role: Principal Investigator 2013 – 2014 AF Wave 1 – Real-world Study Evaluating Dronedarone Treatment Patterns and Outcomes in Patients with Atrial Fibrillation: Wave 1 Sponsor: United Biosource Corporation Role: Principal Investigator

6 Page

Contact this candidate